tiprankstipranks
Trending News
More News >
Hangzhou Tigermed Consulting Co., Ltd. Class H (DE:5HZ1)
FRANKFURT:5HZ1

Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1) Stock Statistics & Valuation Metrics

Compare
1 Followers

Total Valuation

Hangzhou Tigermed Consulting Co., Ltd. Class H has a market cap or net worth of €4.49B. The enterprise value is €63.81B.
Market Cap€4.49B
Enterprise Value€63.81B

Share Statistics

Hangzhou Tigermed Consulting Co., Ltd. Class H has 123,124,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding123,124,800
Owned by Insiders
Owned by Institutions

Financial Efficiency

Hangzhou Tigermed Consulting Co., Ltd. Class H’s return on equity (ROE) is 0.02 and return on invested capital (ROIC) is 1.66%.
Return on Equity (ROE)0.02
Return on Assets (ROA)0.01
Return on Invested Capital (ROIC)1.66%
Return on Capital Employed (ROCE)0.03
Revenue Per Employee648.32K
Profits Per Employee43.97K
Employee Count10,185
Asset Turnover0.23
Inventory Turnover136.47

Valuation Ratios

The current PE Ratio of Hangzhou Tigermed Consulting Co., Ltd. Class H is 61.76. Hangzhou Tigermed Consulting Co., Ltd. Class H’s PEG ratio is -1.15.
PE Ratio61.76
PS Ratio0.00
PB Ratio3.52
Price to Fair Value1.21
Price to FCF75.77
Price to Operating Cash Flow50.73
PEG Ratio-1.15

Income Statement

In the last 12 months, Hangzhou Tigermed Consulting Co., Ltd. Class H had revenue of 6.60B and earned 405.14M in profits. Earnings per share was 0.47.
Revenue6.60B
Gross Profit2.24B
Operating Income664.42M
Pretax Income664.46M
Net Income405.14M
EBITDA1.13B
Earnings Per Share (EPS)0.47

Cash Flow

In the last 12 months, operating cash flow was 33.12M and capital expenditures 0.00, giving a free cash flow of 589.58M billion.
Operating Cash Flow33.12M
Free Cash Flow589.58M
Free Cash Flow per Share4.79

Dividends & Yields

Hangzhou Tigermed Consulting Co., Ltd. Class H pays an annual dividend of €0.036, resulting in a dividend yield of 1.89%
Dividend Per Share€0.036
Dividend Yield1.89%
Payout Ratio74.60%
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.85
52-Week Price Change13.62%
50-Day Moving Average3.32
200-Day Moving Average3.66
Relative Strength Index (RSI)53.87
Average Volume (3m)40.00

Important Dates

Hangzhou Tigermed Consulting Co., Ltd. Class H upcoming earnings date is Aug 21, 2025, TBA Not Confirmed.
Last Earnings DateApr 29, 2025
Next Earnings DateAug 21, 2025
Ex-Dividend DateJun 12, 2025

Financial Position

Hangzhou Tigermed Consulting Co., Ltd. Class H as a current ratio of 1.72, with Debt / Equity ratio of 14.30%
Current Ratio1.72
Quick Ratio1.71
Debt to Market Cap0.09
Net Debt to EBITDA0.51
Interest Coverage Ratio4.70

Taxes

In the past 12 months, Hangzhou Tigermed Consulting Co., Ltd. Class H has paid 216.63M in taxes.
Income Tax216.63M
Effective Tax Rate0.33

Enterprise Valuation

Hangzhou Tigermed Consulting Co., Ltd. Class H EV to EBITDA ratio is 22.66, with an EV/FCF ratio of 34.57.
EV to Sales3.88
EV to EBITDA22.66
EV to Free Cash Flow34.57
EV to Operating Cash Flow23.34

Balance Sheet

Hangzhou Tigermed Consulting Co., Ltd. Class H has €1.68B in cash and marketable securities with ¥2.85B in debt, giving a net cash position of €1.18B billion.
Cash & Marketable Securities€1.68B
Total Debt¥2.85B
Net Cash€1.18B
Net Cash Per Share€9.58
Tangible Book Value Per Share€23.70

Margins

Gross margin is 39.64%, with operating margin of 10.06%, and net profit margin of 6.14%.
Gross Margin39.64%
Operating Margin10.06%
Pretax Margin10.06%
Net Profit Margin6.14%
EBITDA Margin17.11%
EBIT Margin12.20%

Analyst Forecast

The average price target for Hangzhou Tigermed Consulting Co., Ltd. Class H is €4.04, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€4.04
Price Target Upside-1.46% Downside
Analyst ConsensusModerate Buy
Analyst Count4
Revenue Growth Forecast
EPS Growth Forecast

Scores

Smart Score6
AI Score
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis